EUVIMEDEUVIMED entdecken
KohortenstudieOpen Access

COVID-19 Rebound in Nirmatrelvir Plus Ritonavir Treatment and Control Groups: Prospective Cohort Study

Jacqueline K Kueper, Kalyani Kottilil, Giorgio Quer, Danielle C Chiang, Emily G Spencer, Jyothi Purushotham, Edward Ramos, Leila Roumani, Kristian G Andersen, Eric J Topol, Jay A Pandit, Michael J Mina

Interactive Journal of Medical Research · 02.06.2026 · 15 · e80263-e80263

DOI: 10.2196/80263 ↗

Kurz gefasst

Kohortenstudie in der Zeitschrift Interactive Journal of Medical Research, online erschienen am 02.06.2026. Verfasst von Jacqueline K Kueper und 11 weiteren Autor:innen. Beteiligte Einrichtung: Scripps Research Translational Institute, Scripps Research Institute, 10550 North Torrey Pines Road, La Jolla, CA, 92037, United States, 1 858-784-10…. Die Arbeit nennt 31 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Observation of COVID-19 rebound after nirmatrelvir plus ritonavir (NPR) has driven important questions surrounding one of the only direct-acting antiviral treatments for COVID-19.

Objective

The objective of this study was to examine the epidemiology of COVID-19 rebound among COVID-19–positive outpatients in the United States who independently decided whether or not to take NPR.

Methods

This prospective, decentralized observational cohort study was conducted from August 2022 through December 2023 and included frequent proctored COVID-19 rapid antigen tests and self-report symptom surveys for 15 days. The primary outcome was the incidence of viral and symptom rebound. Secondary outcomes included time to initial viral and symptom clearance, rebound probability among patients who cleared by day 15, and symptom frequency.

Results

Of 917 consenting participants, 669 (73%) were eligible for inclusion in the analysis (n=443, 66% in the NPR group; n=226, 34% in the control group). The mean age was 46.1 (SD 12.9) years, 62.6% (n=419) of participants were female, and 49.2% (n=329) had at least one preexisting condition. Overall, 15-day cumulative incidence was higher in the NPR group than the control group for both viral (70/443, 15.8% vs 12/226, 5.3%) and symptom (73/443, 16.5% vs 19/226, 8.4%) rebound. Time to initial viral and symptom clearance was similar between groups, and among those who experienced clearance by day 15, the probability of viral rebound (NPR: 19.1%, 95% CI 15.1%-24.0% vs control: 7%, 95% CI 4.0%-12.6%; P

Schlagwörter

Stichwörter der Autor:innen

COVID-19COVID-19 reboundnirmatrelvir plus ritonavirsymptom reboundviral rebound

Autor:innen und Institutionen

  • Scripps Research Translational Institute, Scripps Research Institute, 10550 North Torrey Pines Road, La Jolla, CA, 92037, United States, 1 858-784-1000.
  • Department of Immunology and Microbiology, Scripps Research Institute, La Jolla, CA, United States.
  • Care Evolution, Ann Arbor, MI, United States.
  • eMed, Miami, FL, United States.
  • Immune Observatory, Boston, MA, United States.

Zitieren

APA

Kueper, J. K., Kottilil, K., Quer, G., Chiang, D. C., Spencer, E. G., Purushotham, J., Ramos, E., Roumani, L., Andersen, K. G., Topol, E. J., Pandit, J. A., & Mina, M. J. (2026). COVID-19 Rebound in Nirmatrelvir Plus Ritonavir Treatment and Control Groups: Prospective Cohort Study. Interactive Journal of Medical Research, 15, e80263-e80263. https://doi.org/10.2196/80263

Vancouver

Kueper JK, Kottilil K, Quer G, Chiang DC, Spencer EG, Purushotham J, et al. COVID-19 Rebound in Nirmatrelvir Plus Ritonavir Treatment and Control Groups: Prospective Cohort Study. Interactive Journal of Medical Research. 2026;15:e80263-e80263. doi:10.2196/80263

BibTeX
@article{Kueper2026,
  author = {Kueper, Jacqueline K and Kottilil, Kalyani and Quer, Giorgio and Chiang, Danielle C and Spencer, Emily G and Purushotham, Jyothi and Ramos, Edward and Roumani, Leila and Andersen, Kristian G and Topol, Eric J and Pandit, Jay A and Mina, Michael J},
  title = {COVID-19 Rebound in Nirmatrelvir Plus Ritonavir Treatment and Control Groups: Prospective Cohort Study},
  journal = {Interactive Journal of Medical Research},
  year = {2026},
  volume = {15},
  pages = {e80263--e80263},
  doi = {10.2196/80263}
}
Kostenlos starten →